clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИ10.37489/2588-0519-2020-S4-99-102clinvest-538Research ArticleАКТУАЛЬНЫЕ ОБЗОРЫACTUAL REVIEWВозможность и перспективы применения препарата ремдесивир у пациентов с COVID-19Current and future use of remdesivir in patients with COVID-19https://orcid.org/0000-0003-4810-2295ЦветовВ. М.TsvetovV. M.

Цветов Виталий Михайлович – к. м. н., врач — клинический фармаколог. SPIN-код: 3202-7659

Челябинск

Tsvetov Vitaly M. – Candidate of Medical Sciences, Doctor — Clinical Pharmacologist. SPIN code: 3202-7659

Chelyabinsk

https://orcid.org/0000-0002-9307-4994МирзаевК. Б.MirzaevK. B.

Мирзаев Карин Бадавиевич – к. м. н., доцент кафедры клинической фармакологии и терапии. SPIN-код: 8308-7599

Москва

Mirzaev Karin B. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8308-7599

Moscow

https://orcid.org/0000-0002-4496-3680СычёвД. А.SychevD. A.

Сычёв Дмитрий Алексеевич – д. м. н., профессор, член-корр. РАН, ректор, зав. кафедрой клинической фармакологии и терапии. SPIN-код: 4525-7556

Москва

Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556

Moscow

dmitriy.alex.sychev@gmail.comФГБУ «Федеральный центр сердечно-сосудистой хирургии» Минздрава РоссииРоссияFederal Center for Cardiovascular Surgery of the Ministry of Health of RussiaRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy of Continuing Professional Education of the Ministry of Health of RussiaRussian Federation20202810202004SФармаCOVID99102Copyright © Цветов В.М., Мирзаев К.Б., Сычёв Д.А., 20202020Цветов В.М., Мирзаев К.Б., Сычёв Д.А.Tsvetov V.M., Mirzaev K.B., Sychev D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/538

Существуют предпосылки к применению препарата ремдесивир против SARS-CoV-2 в стационарных условиях. В настоящее время препарат не зарегистрирован в Российской Федерации. Предварительные результаты рандомизированных клинических исследований эффективности ремдесивира противоречивы.

There are prerequisites for the use of remdesivir against SARS-CoV-2 in stationary conditions. Remdesivir is not registered in the Russian Federation. The preliminary results of randomized clinical trials on the efficacy of remission are contradictory.

коронавирусремдесивирCOVID-19coronavirusremdesivirCOVID-19ReferencesAgostini ML, Andres EL, Sims AC et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018 Mar 6;9(2):e00221-18. DOI: 10.1128/mBio.00221-18Agostini ML, Andres EL, Sims AC et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018 Mar 6;9(2):e00221-18. DOI: 10.1128/mBio.00221-18Sheahan TP, Sims AC, Graham RL et al. Broad-spectrum antiviral GS5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017 Jun 28;9(396):eaal3653. DOI: 10.1126/scitranslmed.aal3653Sheahan TP, Sims AC, Graham RL et al. Broad-spectrum antiviral GS5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017 Jun 28;9(396):eaal3653. DOI: 10.1126/scitranslmed.aal3653Sheahan TP, Sims AC, Leist SR et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222. DOI: 10.1038/s41467-01913940-6Sheahan TP, Sims AC, Leist SR et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222. DOI: 10.1038/s41467-01913940-6«Singapore approves remdesivir drug for emergency COVID-19 treatment». Reuters. Retrieved 10 June 2020.«Singapore approves remdesivir drug for emergency COVID-19 treatment». Reuters. Retrieved 10 June 2020.Wang M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DOI: 10.1038/s41422-020-0282-0Wang M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DOI: 10.1038/s41422-020-0282-0FDA Allows For ‘Emergency Use’ of Remdesivir, Experimental Coronavirus Drug (англ.). TIME. ASSOCIATED PRESS (1 May 2020)FDA Allows For ‘Emergency Use’ of Remdesivir, Experimental Coronavirus Drug (англ.). TIME. ASSOCIATED PRESS (1 May 2020)Herman Steve. Coronavirus Treatment Breakthrough Announced. Voice of America. [Internet]. [cited 2020 April 29]; Available from: https://www.voanews.com/covid-19-pandemic/coronavirus-treatment-breakthrough-announcedHerman Steve. Coronavirus Treatment Breakthrough Announced. Voice of America. [Internet]. [cited 2020 April 29]; Available from: https://www.voanews.com/covid-19-pandemic/coronavirus-treatment-breakthrough-announcedNIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19. National Institute of Allergy and Infectious Diseases (NIAID) [Internet]. [cited 2020 April 29]; Available from: https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-acceleratesrecovery-advanced-covid-19NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19. National Institute of Allergy and Infectious Diseases (NIAID) [Internet]. [cited 2020 April 29]; Available from: https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-acceleratesrecovery-advanced-covid-19Воронин Н. Ученые подтвердили эффективность ремдесивира в лечении коронавируса. Би-би-си BBC News Русская служба. [Электронный ресурс]. Доступно по: https://www.bbc.com/russian/news-52490929 Ссылка активна на 30.04.2020Voronin N. Scientists have confirmed the effectiveness of ramdevpir in the treatment of coronavirus. BBC News Russian service. (In Russ). [Электронный ресурс]. Доступно по: https://www.bbc.com/russian/news-52490929 Ссылка активна на 30.04.2020Beigel JH et al. Remdesivir for the Treatment of Covid-19 Preliminary Report. N Engl J Med. 2020 May 22;NEJMoa2007764. DOI: 10.1056/NEJMoa2007764Beigel JH et al. Remdesivir for the Treatment of Covid-19 Preliminary Report. N Engl J Med. 2020 May 22;NEJMoa2007764. DOI: 10.1056/NEJMoa2007764Gøtzsche PC. Remdesivir against coronavirus, hope or hype? / Prof. Peter C. Gøtzsche — Copenhagen: Institute for Scientific Freedom [Internet]. [cited 2020 June 1]; Available from: https://www.scientificfreedom.dk/wpcontent/uploads/2020/06/Gøtzsche-Remdesivir-against-coronavirus-hopeor-hype.pdfGøtzsche PC. Remdesivir against coronavirus, hope or hype? / Prof. Peter C. Gøtzsche — Copenhagen: Institute for Scientific Freedom [Internet]. [cited 2020 June 1]; Available from: https://www.scientificfreedom.dk/wpcontent/uploads/2020/06/Gøtzsche-Remdesivir-against-coronavirus-hopeor-hype.pdfGoldman JD et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 May 27;NEJMoa2015301. DOI: 10.1056/NEJMoa2015301Goldman JD et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 May 27;NEJMoa2015301. DOI: 10.1056/NEJMoa2015301Search of: Favipiravir — List Results — ClinicalTrials.gov [Internet]. [cited 2020 July 09]; Available from: https://clinicaltrials.gov/ct2/results?cond=&term=&type=&rslt=&age_v=&gndr=&intr=RemdesivirSearch of: Favipiravir — List Results — ClinicalTrials.gov [Internet]. [cited 2020 July 09]; Available from: https://clinicaltrials.gov/ct2/results?cond=&term=&type=&rslt=&age_v=&gndr=&intr=RemdesivirWorld Health Organization (WHO) (2020) Clinical management of COVID-19. Interim Guidance. 27 May. [Internet]. [cited 2020 June 09]; Available from: https://www.who.int/publications/i/item/clinicalmanagement-of-covid-19World Health Organization (WHO) (2020) Clinical management of COVID-19. Interim Guidance. 27 May. [Internet]. [cited 2020 June 09]; Available from: https://www.who.int/publications/i/item/clinicalmanagement-of-covid-19Frequently Asked Questions on the Emergency Use Authorization for Remdesivir for Certain Hospitalized COVID-19 Patients [Internet]. [cited 2020 June 09]; Available from: https://www.fda.gov/media/137574/downloadFrequently Asked Questions on the Emergency Use Authorization for Remdesivir for Certain Hospitalized COVID-19 Patients [Internet]. [cited 2020 June 09]; Available from: https://www.fda.gov/media/137574/downloadCaroline Cassels. COVID-19 Update: Elusive Complication, Remdesivir Toxicity. Medscape Medical News. gov [Internet]. [cited 2020 July 08]; Available from: https://www.medscape.com/viewarticle/933623?src=iphone&ref=email#vp_1Caroline Cassels. COVID-19 Update: Elusive Complication, Remdesivir Toxicity. Medscape Medical News. gov [Internet]. [cited 2020 July 08]; Available from: https://www.medscape.com/viewarticle/933623?src=iphone&ref=email#vp_1Государственный реестр лекарственных средств, реестр разрешений на проведение клинических исследований [РКИ]. [Электронный ресурс]. [Электронный ресурс]. Доступно по: https://grls.rosminzdrav.ru/CiPermitionReg.aspx?Torg=ремдесивир Ссылка активна на 09.07.2020The state register of medicinal products, registry of permits for the conduct of clinical trials [RCTS]. (In Russ). [Электронный ресурс]. Доступно по: https://grls.rosminzdrav.ru/CiPermitionReg.aspx?Torg=ремдесивир Ссылка активна на 09.07.2020

The authors declare that there are no conflicts of interest present.